Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of itacitinib for nonsevere sporadic adult HLH
2021-000407-20Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of itacitinib in haemophagocytic lymphohistiocytosis (HLH), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Overall response rate at day 15. Started Jul 2021; status: active.
02
Drugs
itacitinib
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on 2021-000407-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000407-20.